Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (251-260 of 333) with videos related to

Pageof 34
Sort By:
Alimentary Pharmacology & Therapeutics|December 3, 2024
Early HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation-A Pooled Analysis of Two Clinical TrialsEdo J Dongelmans, Jordan J Feld, André Boonstra, et al.
Gastroenterology|March 23, 2010
Ribavirin improves early responses to peginterferon through improved interferon signalingJordan J Feld, Glen A Lutchman, Theo Heller, et al.
Journal of Gastroenterology and Hepatology|December 10, 2015
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosisAdriaan J van der Meer, Raoel Maan, Bart J Veldt, et al.
Hepatology Communications|November 4, 2022
Leveraging COVID-19 vaccination to promote hepatitis C screeningAaron Vanderhoff, David Smookler, Mia J Biondi, et al.
Hepatology (Baltimore, Md.)|May 1, 2023
Pathway to global elimination of hepatitis B: HBV cure is just the first stepJessica Howell, Chris Seaman, Jack Wallace, et al.
The New England Journal of Medicine|December 31, 2010
Residual NADPH oxidase and survival in chronic granulomatous diseaseDouglas B Kuhns, W Gregory Alvord, Theo Heller, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Journal of Gastroenterology and Hepatology|March 19, 2016
Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosisRaoel Maan, Remziye Zaim, Adriaan J van der Meer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion UpdateJessica P Hwang, Jordan J Feld, Sarah P Hammond, et al.
Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.
Pageof 34

Showing results (251-260 of 333) with videos related to

Sort By:
Pageof 34
Alimentary Pharmacology & Therapeutics|December 3, 2024
Early HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation-A Pooled Analysis of Two Clinical TrialsEdo J Dongelmans, Jordan J Feld, André Boonstra, et al.
Gastroenterology|March 23, 2010
Ribavirin improves early responses to peginterferon through improved interferon signalingJordan J Feld, Glen A Lutchman, Theo Heller, et al.
Journal of Gastroenterology and Hepatology|December 10, 2015
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosisAdriaan J van der Meer, Raoel Maan, Bart J Veldt, et al.
Hepatology Communications|November 4, 2022
Leveraging COVID-19 vaccination to promote hepatitis C screeningAaron Vanderhoff, David Smookler, Mia J Biondi, et al.
Hepatology (Baltimore, Md.)|May 1, 2023
Pathway to global elimination of hepatitis B: HBV cure is just the first stepJessica Howell, Chris Seaman, Jack Wallace, et al.
The New England Journal of Medicine|December 31, 2010
Residual NADPH oxidase and survival in chronic granulomatous diseaseDouglas B Kuhns, W Gregory Alvord, Theo Heller, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Journal of Gastroenterology and Hepatology|March 19, 2016
Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosisRaoel Maan, Remziye Zaim, Adriaan J van der Meer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion UpdateJessica P Hwang, Jordan J Feld, Sarah P Hammond, et al.
Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.
Pageof 34